Long Grove launches premix norepinephrine

Long Grove Pharmaceuticals is offering ready-to-use norepinephrine in 0.9% sodium chloride in the 16 mg/250ml (64 mcg/ml) strength and anticipates the availability of the 4 mg/250 ml (16 mcg/ml) and 8 mg/250 ml (32 mcg/ml) strengths in early summer. 

“This ready-to-use premix has a 24-month shelf life at room temperature and is safe to use up to seven days after removal from the foil overwrap. A new source for norepinephrine is a much needed addition to the fragile critical care supply chain. The convenience and safety of this manufactured premix formulation will help hospital pharmacies focus their limited resources on addressing unique and critical patient needs,” the company said. 

“We’re very happy to help play a role in relieving some of the stresses that our hospital pharmacy colleagues face every day. Over the last six months, we have met with many customers who have shared their ongoing challenges and have been very supportive of our efforts to bring a safe, convenient premix Norepinephrine to market,” said Peter Karas, chief commercial officer of Long Grove Pharmaceuticals.

[Read more: Long Grove gets FDA OK for generic Radicava]

Norepinephrine in 0.9% sodium chloride injection is indicated to raise blood pressure in adult patients with severe, acute hypotension, and it is one of the most commonly used injectable medications in the critical care setting.